ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Mengfan, Tian, Ye, Li, Wang, Li, Dan, Zhao, Tian, Yang, Yuxin, Li, Qiwen, Chen, Sujun, Yang, Yan, Zhang, Zhixiong, Tang, Liang, Liu, Zhonghua, Su, Bo, Li, Fei, Feng, Yonghong, Fei, Ke, Zhang, Peng, Zhang, Fan, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844726/
https://www.ncbi.nlm.nih.gov/pubmed/29552290
http://dx.doi.org/10.18632/oncotarget.24147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844726/
https://www.ncbi.nlm.nih.gov/pubmed/29552290
http://dx.doi.org/10.18632/oncotarget.24147

Ejemplares similares